
Michael L Dourson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2747179/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PFAS Experts Symposium 2: PFAS Toxicology and Risk Assessment in 2021—Contemporary issues in human and ecological risk assessment of PFAS. Remediation, 2022, 32, 29-44.	2.4	7
2	Cobalt: A tiered testing strategy to estimate its inhalation toxicity. Regulatory Toxicology and Pharmacology, 2022, , 105163.	2.7	0
3	The Conundrum of the PFOA human half-life, an international collaboration. Regulatory Toxicology and Pharmacology, 2022, 132, 105185.	2.7	10
4	Suggestions for Improving the Characterization of Risk from Exposures to Per and Polyfluorinated Alkyl Substances. Environmental Toxicology and Chemistry, 2021, 40, 871-886.	4.3	5
5	Analysis for data-derived extrapolation factors for procymidone. Regulatory Toxicology and Pharmacology, 2021, 124, 104972.	2.7	1
6	The Dilemma of perfluorooctanoate (PFOA) human half-life. Regulatory Toxicology and Pharmacology, 2021, 126, 105025.	2.7	11
7	A regulatory relic: After 60Âyears of research on cancer risk, the Delaney Clause continues to keep us in the past. Toxicology and Applied Pharmacology, 2021, 433, 115779.	2.8	2
8	Data derived extrapolation factors for developmental toxicity: A preliminary research case study with perfluorooctanoate (PFOA). Regulatory Toxicology and Pharmacology, 2020, 110, 104502.	2.7	0
9	Bioelution, Bioavailability, and Toxicity of Cobalt Compounds Correlate. Toxicological Sciences, 2020, 174, 311-325.	3.1	24
10	A commentary on some epidemiology data for chlorpyrifos. Regulatory Toxicology and Pharmacology, 2020, 113, 104616.	2.7	4
11	Data derived Extrapolation Factors for developmental toxicity: A preliminary research case study with perfluorooctanoate (PFOA). Regulatory Toxicology and Pharmacology, 2019, 108, 104446.	2.7	5
12	Derivation of a noâ€significantâ€riskâ€level for tetrabromobisphenol A based on a threshold nonâ€mutagenic cancer mode of action. Journal of Applied Toxicology, 2018, 38, 862-878.	2.8	6
13	Benchmark dose (BMD) modeling: current practice, issues, and challenges. Critical Reviews in Toxicology, 2018, 48, 387-415.	3.9	131
14	Let the IRIS Bloom:Regrowing the integrated risk information system (IRIS) of the U.S. Environmental Protection Agency. Regulatory Toxicology and Pharmacology, 2018, 97, A4-A5.	2.7	2
15	Quantitative weight of evidence to assess confidence in potential modes of action. Regulatory Toxicology and Pharmacology, 2017, 86, 205-220.	2.7	50
16	Update: Mode of action (MOA) for liver tumors induced by oral exposure to 1,4-dioxane. Regulatory Toxicology and Pharmacology, 2017, 88, 45-55.	2.7	20
17	Managing risks of noncancer health effects at hazardous waste sites: A case study using the Reference Concentration (RfC) of trichloroethylene (TCE). Regulatory Toxicology and Pharmacology, 2016, 80, 125-133.	2.7	2
18	Advances in assessing ingredient safety. Regulatory Toxicology and Pharmacology, 2016, 79, S112-S118.	2.7	3

#	Article	IF	CITATIONS
19	Bayesian methods for uncertainty factor application for derivation of reference values. Regulatory Toxicology and Pharmacology, 2016, 80, 9-24.	2.7	20
20	Approaches for describing and communicating overall uncertainty in toxicity characterizations: U.S. Environmental Protection Agency's Integrated Risk Information System (IRIS) as a case study. Environment International, 2016, 89-90, 110-128.	10.0	27
21	Whither Risk Assessment: New Challenges and Opportunities a Third of a Century After the Red Book. Risk Analysis, 2015, 35, 1959-1968.	2.7	11
22	A reproductive, developmental and neurobehavioral study following oral exposure of tetrabromobisphenol A on Sprague-Dawley rats. Toxicology, 2015, 329, 49-59.	4.2	66
23	Crystallographic Analysis and Mimicking of Estradiol Binding: Interpretation and Speculation. Environmental Health Perspectives, 2014, 122, A91.	6.0	3
24	Mode of action analysis for liver tumors from oral 1,4-dioxane exposures and evidence-based dose response assessment. Regulatory Toxicology and Pharmacology, 2014, 68, 387-401.	2.7	20
25	A framework for fit-for-purpose dose response assessment. Regulatory Toxicology and Pharmacology, 2013, 66, 234-240.	2.7	14
26	The importance of problem formulations in risk assessment: A case study involving dioxin-contaminated soil. Regulatory Toxicology and Pharmacology, 2013, 66, 208-216.	2.7	3
27	Safety assessment of boron by application of new uncertainty factors and their subdivision. Regulatory Toxicology and Pharmacology, 2013, 65, 108-114.	2.7	16
28	Peer consultation on relationship between PAC profile and toxicity of petroleum substances. Regulatory Toxicology and Pharmacology, 2013, 67, S86-S93.	2.7	7
29	Advancing human health risk assessment: Integrating recent advisory committee recommendations. Critical Reviews in Toxicology, 2013, 43, 467-492.	3.9	42
30	Critical review of dose–response options for F344 rat mammary tumors for acrylamide – Additional insights based on mode of action. Food and Chemical Toxicology, 2012, 50, 1763-1775.	3.6	18
31	Linear low-dose extrapolation for noncancer health effects is the exception, not the rule. Critical Reviews in Toxicology, 2011, 41, 1-19.	3.9	108
32	Derived Reference Doses (RfDs) for the environmental degradates of the herbicides alachlor and acetochlor: Results of an independent expert panel deliberation. Regulatory Toxicology and Pharmacology, 2010, 57, 220-234.	2.7	17
33	Dose response assessment for effects of acute exposure to methyl isothiocyanate (MITC). Regulatory Toxicology and Pharmacology, 2010, 58, 181-188.	2.7	20
34	Proposal of new uncertainty factor application to derive tolerable daily intake. Regulatory Toxicology and Pharmacology, 2010, 58, 237-242.	2.7	18
35	Human chemosensory perception of methyl isothiocyanate: Chemesthesis and odor. Regulatory Toxicology and Pharmacology, 2010, 58, 173-180.	2.7	24
36	Guidelines for the derivation of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology, 2008, 51, S4-S15.	2.7	147

#	Article	IF	CITATIONS
37	Guidelines for the communication of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology, 2008, 51, S16-S26.	2.7	99
38	Evidence-based dose–response assessment for thyroid tumorigenesis from acrylamide. Regulatory Toxicology and Pharmacology, 2008, 52, 264-289.	2.7	36
39	Resources for global risk assessment: The International Toxicity Estimates for Risk (ITER) and Risk Information Exchange (RiskIE) databases. Toxicology and Applied Pharmacology, 2008, 233, 45-53.	2.8	17
40	Data considerations for regulation of water contaminants. Toxicology, 2006, 221, 217-224.	4.2	17
41	A review of the reference dose for chlorpyrifos. Regulatory Toxicology and Pharmacology, 2006, 44, 111-124.	2.7	30
42	Using Best Science in Cancer Risk Assessment. Human and Ecological Risk Assessment (HERA), 2006, 12, 1-8.	3.4	4
43	The NAS Perchlorate Review: Is the RfD Acceptable?. Environmental Health Perspectives, 2005, 113, A729-30; author reply A730-2.	6.0	3
44	lodine-deficient vegetarians: A hypothetical perchlorate-susceptible population?. Regulatory Toxicology and Pharmacology, 2005, 42, 37-46.	2.7	10
45	Lower birth weight as a critical effect of chlorpyrifos: A comparison of human and animal data. Regulatory Toxicology and Pharmacology, 2005, 42, 55-63.	2.7	35
46	Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations. Regulatory Toxicology and Pharmacology, 2005, 43, 1-9.	2.7	66
47	Reference dose for perchlorate based on thyroid hormone change in pregnant women as the critical effect. Regulatory Toxicology and Pharmacology, 2004, 39, 44-65.	2.7	24
48	Health Risks from Eating Contaminated Fish. Comments on Modern Biology Part B, Comments on Toxicology, 2002, 8, 399-419.	0.2	3
49	Framework and Case Studies. Comments on Modern Biology Part B, Comments on Toxicology, 2002, 8, 431-502.	0.2	2
50	Conclusions and Research Needs. Comments on Modern Biology Part B, Comments on Toxicology, 2002, 8, 517-525.	0.2	0
51	Differential Sensitivity of Children and Adults to Chemical Toxicity. Regulatory Toxicology and Pharmacology, 2002, 35, 429-447.	2.7	174
52	Differential Sensitivity of Children and Adults to Chemical Toxicity. Regulatory Toxicology and Pharmacology, 2002, 35, 448-467.	2.7	82
53	Use of Human Data for the Derivation of a Reference Dose for Chlorpyrifos. Regulatory Toxicology and Pharmacology, 2001, 33, 110-116.	2.7	21
54	Using Human Data to Protect the Public's Health. Regulatory Toxicology and Pharmacology, 2001, 33, 234-256.	2.7	33

#	Article	IF	CITATIONS
55	Uncertainties in the Reference Dose for Methylmercury. NeuroToxicology, 2001, 22, 677-689.	3.0	35
56	Using Human Data to Develop Risk Values. Human and Ecological Risk Assessment (HERA), 2001, 7, 1583-1592.	3.4	3
57	Replacing the Default Values of 10 With Data-Derived Values: A Comparison of Two Different Data-Derived Uncertainty Factors for Boron. Human and Ecological Risk Assessment (HERA), 1999, 5, 973-983.	3.4	7
58	Application of Quantitative Information on the Uncertainty in the RfD to Noncarcinogenic Risk Assessments. Human and Ecological Risk Assessment (HERA), 1999, 5, 527-546.	3.4	5
59	Title is missing!. Risk Analysis, 1999, 19, 7-8.	2.7	О
60	Distribution of exposure concentrations and doses for constituents of environmental tobacco smoke. Risk Analysis, 1999, 19, 375-390.	2.7	12
61	Health Risk above the Reference Dose for Multiple Chemicals. Regulatory Toxicology and Pharmacology, 1999, 30, S19-S26.	2.7	26
62	A Probabilistic Framework for the Reference Dose (Probabilistic RfD). Risk Analysis, 1998, 18, 271-282.	2.7	107
63	The Inexact Science of Risk Assessment (and Implications for Risk Management). Human and Ecological Risk Assessment (HERA), 1998, 4, 245-251.	3.4	22
64	EPA's Neurotoxicity Risk Assessment Guidelines. Toxicological Sciences, 1997, 40, 175-184.	3.1	4
65	Evolution of scienceâ€based uncertainty factors in noncancer risk assessment. Human and Ecological Risk Assessment (HERA), 1997, 3, 579-589.	3.4	163
66	Hexavalent Chromium-Contaminated Soils: Options for Risk Assessment and Risk Management. Regulatory Toxicology and Pharmacology, 1997, 25, 43-59.	2.7	36
67	Categorical Regression of Toxicity Data: A Case Study Using Aldicarb. Regulatory Toxicology and Pharmacology, 1997, 25, 121-129.	2.7	38
68	An Approach for Modeling Noncancer Dose Responses with an Emphasis on Uncertainty. Risk Analysis, 1997, 17, 427-437.	2.7	49
69	Route-to-Route Extrapolation of the Toxic Potency of MTBE. Risk Analysis, 1997, 17, 717-725.	2.7	18
70	Evolution of Science-Based Uncertainty Factors in Noncancer Risk Assessment. Regulatory Toxicology and Pharmacology, 1996, 24, 108-120.	2.7	239
71	Improvements in Quantitative Noncancer Risk Assessment. Toxicological Sciences, 1993, 20, 1-14.	3.1	4
72	On Reference Dose (RFD) and Its Underlying Toxicity Data Base. Toxicology and Industrial Health, 1992, 8, 171-189.	1.4	71

#	Article	IF	CITATIONS
73	Fish consumption advisories: Toward a unified, scientifically credible approach. Regulatory Toxicology and Pharmacology, 1990, 12, 161-178.	2.7	18
74	Reference dose (RfD): Description and use in health risk assessments. Regulatory Toxicology and Pharmacology, 1988, 8, 471-486.	2.7	491
75	Novel Methods for the Estimation of Acceptable Daily Intake. Toxicology and Industrial Health, 1985, 1, 23-41.	1.4	62
76	Regulatory history and experimental support of uncertainty (safety) factors. Regulatory Toxicology and Pharmacology, 1983, 3, 224-238.	2.7	387
77	Reduced prevalence and growth rate of urethane induced lung adenomas in ageing adult strain a mice. Toxicology, 1981, 20, 165-172.	4.2	10
78	Effects of cytosine arabinoside on in vivo and in vitro mouse limb development. In Vitro, 1977, 13, 434-442.	1.2	5